Patrick A. McBrayer

Exogen, Inc. designs, develops, manufactures and markets medical devices for treatment of musculoskeletal injury and disease. The company's products include sonic acclerated fracture healing system and mechanical stress devices. The products are sold in the United States, Europe and Japan.

Osteotech, Inc. develops biologic products for orthopedic, spinal, trauma, neurosurgical, and maxillofacial surgeons for use in surgical procedures. It operates in five segments: demineralized bone matrix, hybrid/synthetic, traditional tissue, spinal allograft, and client services. The company processes, markets, and distributes Xenograft bone tissue products, which are used as bone graft substitutes. The company was founded in 1986 and is headquartered in Eatontown, NJ.

Misonix, Inc. is a medical device company, which engages in the design, development, manufacture and marketing of therapeutic ultrasonic medical devices. It operates through the following segments: Surgical and Wound. The Surgical segment consists of BoneScalpel and SonaStar products. The Wound segment consists of SonicOne, TheraSkin and Therion products. The company's ultrasonic medical devices are used in the following surgeries: spine, neuro, orthopedic, wound debridement, cosmetic, laparoscopic, and medical applications. The company was founded by Howard Alliger in 1959 and is headquartered in Farmingdale, NY.

AxioMed Spine Corp. was formed in 2001 to develop products with a goal of restoring spinal function to patients with degenerative spine disease; thus advancing the standard of care beyond fusion and first generation artificial discs. Since its inception, AxioMed has secured over $34M in private equity financing from prestigious venture capitalists. The company´s Freedom Lumbar Disc has been developed and clinical trials initiated. The company is headed by CEO, Patrick McBrayer, who joined AxioMed in early 2006. Mr. McBrayer along with founder and COO, James Kuras, lead an experienced management and development team with significant history and expertise in spinal implants, including early artificial disc development efforts. Company employment includes professionals with extensive spine and engineering experience. The team is augmented by a Medical Advisory Panel of surgeons from leading spine centers and universities. The company´s headquarters include product development and testing, clinical and regulatory affairs, and manufacturing. AxioMed will leverage its background in lumbar disc replacement with an ongoing development project for the cervical spine.

Xylos Corp. provides biotechnology solutions. The firm operates as a medical device company that offers superior biomaterial solutions for the treatment, repair and replacement of human tissue. The company was founded by Gonzalo C. Serafica in 1996 and is headquartered in Newtown, PA.

ACell, Inc. develops and manufactures bioscaffold, extracellular matrix technology for medical and veterinary products. It offers the next generation of regenerative medicine through the development and commercialization of unique extracellular matrix devices to repair and remodel damaged tissues and organs in a broad range of surgical procedures. The firm's products include ABRA, Cytal Burn Matrix, Cytal Wound Matrix, Gentrix Surgical Matrix and MicroMatrix. It is a regenerative medicine company that focuses on the development, manufacturing and sale of products primarily used in acute care settings as part of the treatment and management of moderate to severe wounds and reinforcement of soft tissue surgical defects. The firm’s products utilizes proprietary porcine urinary bladder matrix platform technology, which is designed to enhance the body's ability to restore natural tissue and minimize scarring in the management of traumatic, surgical and chronic wounds, burns, hernias and other conditions requiring the reinforcement of soft tissue. The company was founded by Stephen Xavier Graham in June 1999 and is headquartered in Columbia, MD.

Transave, Inc. is a biopharmaceutical company focused on developing innovative, inhaled pharmaceuticals for the site-specific treatment of serious lung diseases such as pulmonary infections in cystic fibrosis patients and cancers affecting the lung. They are committed to significantly improving the quality of life and healthcare of patients suffering from these life-threatening diseases. Its operating principles are centered on teamwork, openness, mutual respect, diversity of opinion, trust, accountability and innovative science. They are developing products based on Transave's proprietary liposomal technology designed specifically for lung delivery. Its focus is on reformulating off-patent, established drugs into unique liposomal technology - based inhaled pharmaceuticals for the localized, site-specific treatment of serious lung diseases. Transave's proprietary liposomal technology allows for the sustained release of a drug in the lung's microenvironment. By remaining in the lungs for a prolonged period and potentially minimizing systemic exposure, Transave's liposomal technology offers the potential for changing the product profile, improving delivery of the compound to the lung and enhancing the therapeutic index of established pharmaceuticals.

The West Point Association of Graduates publishes memorial articles in memory of deceased graduates and former cadets. It offers support west point, read class notes, online gift shop and USAA credit card. The company was founded in 1869 and is headquartered in West Point, NY.